CHMP recommends approval of Buvidal® (CAM2038) for the treatment of opioid dependence
· On approval, Buvidal® would be the first long-acting medicine for treatment of opioid dependence in the EU · A final decision by the European Commission is expected November 2018 Lund, Sweden – 21 September 2018 — Camurus (NASDAQ STO: CAMX) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use, CHMP, has adopted a positive opinion recommending approval of Buvidal® (buprenorphine) prolonged-release solution for injection for treatment of opioid dependence in adults and adolescents from 16 years of age. The final marketing authorisation